Form 4: Day One Biopharmaceuticals Acquired by Servier

Director Natalie C. Holles reports the disposal of all equity holdings following the completion of Day One Biopharmaceuticals' acquisition by Servier Pharmaceuticals.

Summary

• Day One Biopharmaceuticals, Inc. (DAWN) has been acquired by Servier Pharmaceuticals LLC.
• The merger was finalized on April 23, 2026.
• Reporting person Natalie C. Holles disposed of 57,310 shares of common stock at the merger consideration price.
• All outstanding stock options and restricted stock units (RSUs) held by the reporting person were canceled and converted into the right to receive cash payments based on the merger consideration.
• The merger consideration was set at $21.50 per share in cash.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the final exit of a public company following a completed acquisition.

Positives

• Shareholders received a cash payout of $21.50 per share upon the closing of the merger.
• All unvested stock options and RSUs were accelerated and became fully vested immediately prior to the merger effective time.

Negatives

• The company is no longer a publicly traded entity as it has become a wholly owned subsidiary of Servier Pharmaceuticals.

Risks

• The company has ceased independent operations as a public entity, eliminating future upside potential for public shareholders.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Servier Pharmaceuticals; therefore, no further public guidance or forward-looking statements are applicable.

Management Comments

• The filing confirms the completion of the merger agreement where the company survives as a wholly owned subsidiary of Servier Pharmaceuticals.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of consolidation in the biopharmaceutical sector, where larger established players like Servier are acquiring specialized firms to bolster their oncology and rare disease pipelines.

Comparison to Industry Standards

• The acquisition follows standard industry practices for all-cash take-private transactions in the biotech sector.
• The acceleration of unvested equity awards is a common provision in change-of-control agreements to ensure alignment between management and shareholders during an exit.

Corporate Governance

Stakeholder Impact

• Shareholders have received cash consideration for their holdings.
• Employees and management are now part of the Servier Pharmaceuticals organization.

Next Steps

• Delisting of Day One Biopharmaceuticals (DAWN) from public exchanges.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, Merger, Acquisition, Servier Pharmaceuticals, Form 4, Insider Disposal